Evidence map›Paper›PMID 39858470›Full record

ArticleBiomolecules2025

Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma.

Nadia St Thomas, Benjamin N Christopher, Leticia Reyes, Reeder M Robinson, Lena Golick, Xiaoyi Zhu, Eli Chapman, Nathan G Dolloff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nadia St ThomasDepartment of Pharmacology and Immunology, Medical University of South Carolina, 173 Ashley Ave., MSC509, Charleston, SC 29425, USA.ORCID 0000-0002-2090-4491
Benjamin N ChristopherDepartment of Pharmacology and Immunology, Medical University of South Carolina, 173 Ashley Ave., MSC509, Charleston, SC 29425, USA.
Leticia ReyesDepartment of Pharmacology and Immunology, Medical University of South Carolina, 173 Ashley Ave., MSC509, Charleston, SC 29425, USA.
Reeder M RobinsonDepartment of Pharmacology and Immunology, Medical University of South Carolina, 173 Ashley Ave., MSC509, Charleston, SC 29425, USA.
Lena GolickDepartment of Pharmacology and Immunology, Medical University of South Carolina, 173 Ashley Ave., MSC509, Charleston, SC 29425, USA.ORCID 0000-0003-0669-8190
Xiaoyi ZhuDepartment of Pharmacology and Therapeutics, Center for Inflammation Science and Systems Medicine, University of Florida Scripps Institute for Biomedical Innovation and Technology, Jupiter, FL 33458, USA.ORCID 0000-0002-2049-9561
Eli ChapmanDepartment of Pharmacology and Therapeutics, Center for Inflammation Science and Systems Medicine, University of Florida Scripps Institute for Biomedical Innovation and Technology, Jupiter, FL 33458, USA.ORCID 0000-0002-6310-1664
Nathan G DolloffDepartment of Pharmacology and Immunology, Medical University of South Carolina, 173 Ashley Ave., MSC509, Charleston, SC 29425, USA.

Funding

Inhibitors of Oxidative Protein Folding For The Treatment of CancerR01CA245081 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DOLLOFF, NATHAN G. · 2020 to 2024
$2.4M
NCI NIH HHS R01 CA245081NIH HHS R01CA245081
6 · The paper itself

Abstract

Cutaneous T-cell lymphoma (CTCL) is a rare T-cell malignancy characterized by inflamed and painful rash-like skin lesions that may affect large portions of the body's surface. Patients experience recurrent infections due to a compromised skin barrier and generalized immunodeficiency resulting from a dominant Th2 immune phenotype of CTCL cells. Given the role of the unfolded protein response (UPR) in normal and malignant T-cell development, we investigated the impact of UPR-inducing drugs on the viability, transcriptional networks, and Th2 phenotype of CTCL. We found that CTCL cells were >5-fold more sensitive to the proteasome inhibitor bortezomib (Btz) and exhibited a distinct signaling and transcriptional response compared to normal CD4+ cells. The CTCL response was dominated by the induction of the HSP70 family member

Indexed as

Lymphoma, T-Cell, CutaneousSkin NeoplasmsUnfolded Protein ResponseBortezomibCell Line, TumorEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSP70 Heat-Shock ProteinsHumansSignal TransductionBortezomibEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSP70 Heat-Shock ProteinsHSPA5 protein, humanbortezomibcutaneous T-cell lymphomaER stressHSP70HSPA5HSPA6unfolded protein response

Identifiers

PMID39858470
PMCPMC11763779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.